Loading...
•
Jun 30, 2024
Teva Q2 2024 Earnings Report
Teva reported strong revenue growth driven by generics and AUSTEDO, and raised its 2024 financial guidance.
Key Takeaways
Teva's Q2 2024 revenues reached $4.2 billion, a 7% increase in U.S. dollars or 11% in local currency, driven by generics and innovative businesses. AUSTEDO grew 32% in the U.S. The company is raising its financial guidance for 2024.
Global revenues increased by 7% to $4.2 billion, or 11% in local currency.
AUSTEDO revenues in the U.S. increased by 32%.
Non-GAAP diluted earnings per share increased to $0.61, compared to $0.56 in the second quarter of 2023.
The company raised its financial guidance for 2024.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Teva is raising its financial guidance for 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...